Pioglitazone (PIO)

DRUG3 trials

Sponsors

Mayo Clinic, Fudan University, Badr University

Conditions

Breast CancerDiabetes MellitusNon-alcoholic Fatty Liver Disease NAFLDNon-alcoholic Steatohepatitis NASHPancreatitis, AcutePancreatitis, Chronic

Phase 2

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

RecruitingNCT06729996

Mayo ClinicDiabetes Mellitus, Pancreatitis, Acute, Pancreatitis, Chronic

Start: 2025-05-29End: 2027-05-31Target: 40Updated: 2026-04-03

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

RecruitingNCT07117630

Fudan UniversityBreast Cancer

Start: 2025-09-25End: 2027-12-01Target: 60Updated: 2026-07-13

Phase 4

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Not yet recruitingNCT07180745

Badr UniversityNon-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH

Start: 2025-11-01End: 2026-03-01Target: 400Updated: 2025-09-18